Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02485730 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Identification of Markers in Alzheimer's Families / ALFA

Study acronym: ALFA Cohort
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 31, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2025v12
  2. Re-verified, no change to tracked fieldsv11
  3. Primary completion date: Jan 31, 2023 to Dec 31, 2024
    • Study completion date: Jan 31, 2024 to Dec 31, 2025
    v10
  4. Primary completion date: Jul 31, 2022 to Jan 31, 2023v9
  5. Primary completion date: Dec 31, 2020 to Jul 31, 2022v8 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 419
    • Study completion date: Jan 2024 to Jan 31, 2024
    • Site details revised
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: May 31, 2019 to Dec 31, 2020v7
  2. Primary completion date: Jan 2019 to May 31, 2019v6
  3. Primary completion date: Oct 2018 to Jan 2019
    • Study completion date: Oct 2024 to Jan 2024
    v5
  4. Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Primary completion date: Sep 2018 to Oct 2018
    • Study completion date: Oct 2024
    • Start date: Oct 2016 to Oct 25, 2016
    • Study description revised
    • Site details revised
    • Eligibility criteria shortened, about 5 words
  5. Primary completion date: Nov 2017 to Sep 2018
    • Start date: Apr 2016 to Oct 2016
    v3
  6. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The ALFA study is a long term, prospective, observational study of AD patients' adult children aimed at studying and characterizing key physio-pathological features of the preclinical phase of AD.
Trial Details
NCT Number NCT02485730
Lead Sponsor Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Collaborators: Obra Social La Caixa, Spain
Conditions
(from sponsor)		 Alzheimer's Disease
Related terms Alzheimer Disease
Enrollment 419 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov